Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:
• Patients with a confirmed diagnosis of HFpEF.
• Age ≥65 years old
Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Abbie Macher, BS
ajmacher@mgh.harvard.edu
617-643-6328
Backup
Laura Stockhausen, BS
lstockhausen@mgh.harvard.edu
617-724-1339
Time Frame
Start Date: 2020-10-02
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 515
Treatments
Experimental: Patients 65 and older with Heart Failure with Preserved Ejection Fraction
Patients 65 years and older presenting to Massachusetts General Hospital with a known diagnosis of HFpEF and without a diagnosis of amyloidosis in the ambulatory (outpatient) setting will undergo a 99Tc-Pyrophosphate Scan to identify Cardiac Amyloidosis
Related Therapeutic Areas
Sponsors
Collaborators: Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Eidos Therapeutics, a BridgeBio company
Leads: Massachusetts General Hospital